RT Journal Article
T1 Antileukotrienes Improve Naso-Ocular Symptoms and Biomarkers inPatients With NARES and Asthma
A1 De Corso, Eugenio
A1 Anzivino, Roberta
A1 Galli, Jacopo
A1 Baroni, Silvia
A1 Di Nardo, Walter
A1 De Vita, Carla
A1 Salvati, Antonio
A1 Autilio, Chiara
A1 Settimi, Stefano
A1 Mele, Dario
A1 Paludetti, Gaetano
A1 Mullol, Joaquin
AB Objective: The aim of our study was to analyze the montelukast effectiveness in improving oculonasal symptoms, patient-reported outcomes (PROs), and eosinophilic biomarkers in patients with nonallergic rhinitis eosinophilic syndrome (NARES).Methods: We enrolled prospectively 80 symptomatic patients treated with 10 mg once a day of montelukast in mono-therapy for 2 months. All patients were investigated before and after treatment. Nasal symptoms (nasal obstruction, rhinor-rhoea, sneezing, nasal itching), ocular symptoms (redness/puffiness, watery eyes), and other PROs (olfactory dysfunction,difficulty going to sleep, nighttime awakenings, and nasal congestion on awakening) were scored by visual analogic scale. Thefollowing clinical scores were assessed: Total Nasal Symptom Score (T4NSS), Total Ocular Symptom Score (T2OSS), TotalSymptom Score of Patient-Reported Outcomes (TSS-PROs), and a Composite Symptoms Score (CSS). Patients were classified asresponders when a reduction of at least 50% of the CSS was observed. Before and after treatment, the eosinophilic biomarkersin nasal lavage were analyzed: nasal eosinophilia (number of eosinophils per high power field), eotaxin-1 and eotaxin-2.Results: Aft er tre atment, s ig nificant reductions were observed for all the symptom scores. Forty-two of 78 patients were con-sidered responders. A significant reduction of eosinophils in nasal mucosa and of levels of eotaxin-1 and eotaxin-2 in nasal lavagewere observed after treatment in responder patients. Patients with asthma had an increased probability to be responders.Conclusion: NARES patients may benefit from treatment with montelukast. In particular, the presence of concomitantasthma may be predictive of a greater efficacy.
PB Wiley
SN 1531-4995
YR 2019
FD 2019
LK https://hdl.handle.net/20.500.14352/13586
UL https://hdl.handle.net/20.500.14352/13586
LA eng
DS Docta Complutense
RD 7 abr 2025